Viva Biotech Holdings (HKSE:01873) Days Sales Outstanding : 66.66 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Viva Biotech Holdings Days Sales Outstanding?

Viva Biotech Holdings's average Accounts Receivable for the six months ended in Dec. 2023 was HK$405 Mil. Viva Biotech Holdings's Revenue for the six months ended in Dec. 2023 was HK$1,108 Mil. Hence, Viva Biotech Holdings's Days Sales Outstanding for the six months ended in Dec. 2023 was 66.66.

The historical rank and industry rank for Viva Biotech Holdings's Days Sales Outstanding or its related term are showing as below:

HKSE:01873' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.24 Med: 69.71 Max: 98.77
Current: 66.7

During the past 8 years, Viva Biotech Holdings's highest Days Sales Outstanding was 98.77. The lowest was 58.24. And the median was 69.71.

HKSE:01873's Days Sales Outstanding is ranked better than
53.6% of 888 companies
in the Biotechnology industry
Industry Median: 72.545 vs HKSE:01873: 66.70

Viva Biotech Holdings's Days Sales Outstanding declined from Dec. 2022 (67.13) to Dec. 2023 (66.66).

Viva Biotech Holdings Days Sales Outstanding Historical Data

The historical data trend for Viva Biotech Holdings's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viva Biotech Holdings Days Sales Outstanding Chart

Viva Biotech Holdings Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

63.15

98.77

63.69

68.74

70.79

Viva Biotech Holdings Semi-Annual Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial									72.62	75.76	67.13	62.89	66.66

Competitive Comparison of Viva Biotech Holdings's Days Sales Outstanding

For the Biotechnology subindustry, Viva Biotech Holdings's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viva Biotech Holdings's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Viva Biotech Holdings's Days Sales Outstanding falls into.

Viva Biotech Holdings Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Viva Biotech Holdings's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (482.963	+	431.549)	/	2 )	/	2357.726	*	365
=	457.256					/	2357.726	*	365
=	70.79

Viva Biotech Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (378.125	+	431.549)	/	2 )	/	1108.429	*	365 / 2
=	404.837					/	1108.429	*	365 / 2
=	66.66

Viva Biotech Holdings (HKSE:01873) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Viva Biotech Holdings Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Viva Biotech Holdings's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Viva Biotech Holdings (HKSE:01873) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viva Biotech Holdings (HKSE:01873) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

VBIZF:USA VB0:Germany

Address

735 Ziping Road, Pudong New District, Zhoupu Town, Shanghai, CHN, 201318

Website

https://www.vivabiotech.com

Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.

Executives

Mao Chen Cheney	2101 Beneficial owner
Wu John Jiong	2201 Interest of corporation controlled by you
Fenghe Harvest Ltd	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Mao Jun	2501 Other
Temasek Holdings (private) Limited	2201 Interest of corporation controlled by you
Zhou Min	2202 Interest of your spouse
Intertrust (singapore) Ltd.	2301 Trustee
Z&m International Holdings Limited	2201 Interest of corporation controlled by you
Zhang And Sons Limited	2101 Beneficial owner

Viva Biotech Holdings (HKSE:01873) Headlines

No Headlines